MK-677, known by its Merck designation and sometimes written as MK0677, is not a peptide. It is an orally bioavailable molecule that produces a peptide-like effect by acting as a growth hormone secretagogue receptor 1A agonist. By mimicking the N-terminal residues of ghrelin, it binds in the hypothalamus and pituitary, stimulates growth hormone releasing hormone, and reduces somatostatin tone. The result is amplified pulsatile growth hormone secretion rather than the continuous, super-physiologic exposure seen with exogenous growth hormone. Because the pulses are preserved, negative feedback from rising IGF-1 stays intact.

The pharmacology is well characterized. MK-677 has roughly 60 percent oral bioavailability, a half-life near 4.7 hours, and can sustain growth hormone elevations for up to 24 hours. Activation works primarily through the Gq11 pathway, driving PLC-beta, IP3, an intracellular calcium surge, and DAG-mediated PKC signaling that sustains the response. Receptor desensitization is possible, which is why cycling matters.

Across multiple phase two trials, the evidence is consistent on several points:

• IGF-1 elevation: A roughly 40 percent increase in obese males at eight weeks at 25 mg, with sustained elevation reported over twelve months in studied populations.
• Body composition: Increased lean and free fat mass, with anti-catabolic effects shown by reversal of diet-induced negative nitrogen balance.
• Bone: When combined with the bisphosphonate alendronate, femoral neck bone mineral density gains exceeded alendronate alone, pairing reduced resorption with growth hormone and IGF-1 driven formation.
• Sleep: Increased stage four sleep duration was reported.

The cautions are equally important. MK-677 is investigational and not FDA approved. It completed phase two trials but never advanced to phase three, in part because of edema and hemodynamic concerns. The FDA flagged congestive heart failure risk, and one trial was terminated early, though the speaker notes no data showed actual cardiac injury. Growth hormone acts as a counterregulatory hormone, so transient rises in fasting glucose can occur. The recommended approach is to address metabolic issues first, often with a GLP-1 receptor agonist, before considering a secretagogue. Contraindications discussed include active or prior malignancy, congestive heart failure, uncontrolled diabetes with retinopathy, and pregnancy.

It is not one peptide that is going to fix anything. This is a much more complicated picture than a single secretagogue.

On dosing, the speaker favors starting at 12.5 mg at night rather than 25 mg, since lower doses can reach near-maximal growth hormone release while reducing edema, with a typical cycle of twelve weeks on and four to six weeks off. Monitoring may include baseline and follow-up IGF-1, fasting glucose, A1C, lipids, BMP, clinical edema assessment, and DEXA or InBody testing each quarter.

Key clinical points

• MK-677 is an orally bioavailable, non-peptide growth hormone secretagogue receptor 1A agonist that amplifies pulsatile growth hormone release while preserving IGF-1 negative feedback.
• It is investigational and not FDA approved; it completed phase two trials but did not advance to phase three, in part because of edema and hemodynamic concerns including a flagged congestive heart failure risk.
• Reported effects include roughly 40 percent IGF-1 elevation in obese males at eight weeks at 25 mg, increased lean and free fat mass, anti-catabolic reversal of diet-induced negative nitrogen balance, added femoral neck bone mineral density when paired with alendronate, and increased stage four sleep.
• Because growth hormone is counterregulatory, transient rises in fasting glucose can occur, so metabolic issues are addressed first, often with a GLP-1 receptor agonist, before considering a secretagogue.
• The discussed approach favors a lower 12.5 mg nightly start with cycling of twelve weeks on and four to six weeks off, monitoring IGF-1, fasting glucose, A1C, lipids, BMP, clinical edema, and quarterly DEXA or InBody; contraindications include active or prior malignancy, congestive heart failure, uncontrolled diabetes with retinopathy, and pregnancy.